The UK’s drug watchdog is reconsidering two Alzheimer’s disease medicines after rejecting them for being too expensive.
The National Institute for Health and Care Excellence last year determined that Eli Lilly’s donanemab, marketed as Kisunla …
Welcome to another edition of Endpoints Weekly — and happy spring! The weather may not feel very spring-like here in NYC (outside that false start
The FDA is seeking feedback ahead of a public meeting this summer to evaluate the progress of a voucher pilot that has so far accelerated
The lead drug pricing negotiator at the White House said the overarching goal of TrumpRx is to improve price transparency, not to be a large
Plus, news about Gilead, Assembly Biosciences and Pfizer: 📁 Sarepta says FDA open to a filing for full approval of two Duchenne drugs: After a
The US-headquartered, China-rooted biotech Earendil Labs said it has raised $787 million in private money, a whopping sum to fund an AI platform that has
The UK’s drug watchdog is reconsidering two Alzheimer’s disease medicines after rejecting them for being too expensive.
The National Institute for Health and Care Excellence last year determined that Eli Lilly’s donanemab, marketed as Kisunla …